dose of cagrilintide protocol Once-weekly for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial CAGRILINTIDE (5MG) : COA Tested – cagrilintide dosage Chart Cagrilintide Dosage

This can lead to the production of Anti-Drug Antibodies (ADAs)

Cagrilintide + Tirzepatide Storage & Handling Storage Reference (Both Compounds) State Lyophilized (long-term) Tirzepatide -4 F (-20 C), 12+ months Cagrilintide -4 F (-20 C), 12+ months State Lyophilized (short-term) Tirzepatide 35.6-46.4 F (2-8 C), several months Cagrilintide 35.6-46.4 F (2-8 C), several months State Reconstituted (liquid) Tirzepatide 35.6-46.4 F (2-8 C), 28-30 days Cagrilintide 35.6-46.4 F (2-8 C), 28-30 days State Color when reconstituted Tirzepatide Clear, colorless Cagrilintide Clear, colorless State Shake

Misra M Obesity Pharmacotherapy: Current Perspectives and Future Directions Current Cardiology Reviews (2013) 4

If GI side effects are manageable, add cagrilintide at 0.25 mg weekly starting in week 5, while simultaneously increasing retatrutide to 2 mg as per its standard titration